Kenai Therapeutics

We are honored that Dr. Yoshiko Stowell, PhD, RAC, PMP, has been selected as a member of the Alliance for Regenerative Medicine's Women’s Executive Forum! Dr. Stowell joins a compassionate community of leaders committed to promoting gender diversity and supporting the next generation of leaders in our field. Learn more about ARM's Advisory Groups and Forums here: https://bit.ly/3WTzw5Q

We're thrilled to unveil the new and improved KenaiTx.com! Our new site reflects our unique scientific approach to curing neurological conditions, while simultaneously celebrating the natural landscape of Kenai, Alaska - our namesake. Check out our website to learn more. Thank you to Pinkergreen for their exceptional design work!

We are excited to congratulate Dr. Yoshiko Stowell, PhD, RAC, PMP, VP of Regulatory Affairs, for being honored by RAPS with the prestigious Community Leadership Award! This well-deserved award recognizes Dr. Stowell’s outstanding commitment and service as a RAPS ambassador, and her dedication to supporting and uplifting fellow regulatory professionals in her community. Read more about this year’s RAPS award winners here: https://bit.ly/4c6jxGV

Congratulations to SDBJ's 2024 Leaders of Influence in Life Sciences! https://lnkd.in/g4EVhRvE #SDBJ #LifeSciences #YearAwards

Congratulations to Dr. Howard Federoff for being named one of San Diego Business Journal's Leaders of Influence in Life Sciences! As his colleagues, we are inspired by his tireless dedication to the life science industry and his extensive contributions to the field of nervous system disorders. Read more about his work, and all of the other incredible leaders honored, in this issue here: https://bit.ly/4bUgMZo

2024 is starting off with a bang in the iPSC community. With the emergence of two new iPSC-focused biotechs, Kenai Therapeutics and Shinobi Therapeutics, it's clear excitement is developing in stem cell therapeutics and more is still to come. With support from BioInformant, the Hanson Wade Group will be re-uniting the entire iPSC community once again at the 4th iPSC Drug Development & Manufacturing Summit taking place in Boston, October 1-3. By attending you can uncover brand new clinical data from trailblazing iPSC companies including Kenai Therapeutics, Aspen Neuroscience, Inc., and National Institute of Standards and Technology (NIST). The esteemed speaker faculty who will share unmissable data includes: - Kim Raineri, Chief Technology Officer, Aspen Neuroscience, Inc. - Wei Li, Chief Scientific Officer, Cytovia Therapeutics - Howard Federoff, Chief Medical Officer & Co-Founder, Kenai Therapeutics - Allen Feng, Founder & Chief Scientific Officer, HebeCell - Michael Naso, Senior Vice President, Cell Engineering, Century Therapeutics, Inc -Joseph Wu, Professor & Director, Stanford Cardiovascular Institute - Anne Plant, Chief, Biosystems & Biomaterials Division, National Institute of Standards and Technology (NIST) - Takehiko Kaneko, Head of R&D & Chief Medical Officer, Heartseed Inc. You can join these industry leaders and many more, as they discuss the most cutting-edge research in the iPSC community including approaches to enhance iPSC differentiation, integrating AI and automation and tackling new challenges like Parkinson’s Disease and solid tumors. To learn more, view the full session details here: https://lnkd.in/gy2HJ6RD #ipscells #stemcells #celltherapy #drugdevelopment #personalizedmedicine Lara Chick

Today, on #WorldParkinsonsDay, we stand in support of the Parkinson's community worldwide. Parkinson's disease (PD) is a complex neurological condition that affects millions of people around the world, impacting not only individuals but also their families and caregivers. That's why it's more important than ever to reaffirm our commitment to raising awareness, fostering understanding, and driving progress in PD research. Together, we can make a difference in the lives of PD patients and their loved ones. Read about the #ABCsofPD from the Parkinson's Foundation here: https://lnkd.in/gFDYmuri

Kenai Therapeutics has secured an impressive $82 million Series A funding to advance its pioneering work in Parkinson’s disease treatment. Led by esteemed investors, this funding will propel the development of RNDP-001, a promising dopamine progenitor cell therapy, through crucial milestones, including IND submission and Phase I trials. With encouraging preclinical data and the support of industry leaders, including esteemed scientific co-founders, Kenai is aiming to impact the Parkinson’s treatment landscape. CIRM's prior investment of $4 million in February 2023 highlights our confidence in Kenai’s innovative approach and reinforces our commitment to advancing treatments for Parkinson's.

#ParkinsonsAwarenessMonth is an opportunity to raise awareness about the experiences of patients with Parkinson’s disease (PD) and their caregivers, as well as share updates about cutting-edge research developments. At Kenai, we are dedicated to advancing therapeutics with the potential to modify and reverse disease progression in patients with PD. Learn more about how to support Parkinson’s research from The Michael J. Fox Foundation for Parkinson's Research: https://bit.ly/4atuN0p

We’re excited to share that our portfolio company, Kenai Therapeutics, recently closed an $82M Series A financing. Kenai is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company’s platform replaces neurons lost due to neurodegeneration in the brain in order to dramatically alter outcomes for patients. RNDP-001, the Company’s lead candidate, is being developed for the treatment of Parkinson’s disease and is currently in IND-enabling studies. Proceeds from the financing will enable the Company to submit an IND and initiate Phase 1 clinical trials within the next year. Parkinson’s disease affects millions of people worldwide, and the potentially curative nature of RNDP-001 can dramatically alter outcomes for patients with very few treatment options. Congratulations to the Kenai team on this significant milestone! We’re looking forward to what’s to come. Read the press release below:    #venturecapital #lifescience #biotech